Thousand Oaks, California-based Amgen Inc. (AMGN) is a leading independent biotechnology company that discovers, develops, manufactures, and delivers innovative biologic medicines for serious diseases. With a market capitalization of approximately $197.7 billion, the company focuses on oncology, inflammation, general medicine, and rare diseases, leveraging advanced human genetics and biologics manufacturing to improve patient outcomes globally.
AMGN is set to report its Q2 earnings on Wednesday, August 5, 2026, after the market closes. Ahead of the release, analysts expect the company to report a diluted EPS of $5.57, down 7.5% from $6.02 in the year-ago quarter. AMGN has exceeded Wall Street's EPS estimates in each of the past four trailing quarters, which is impressive.